Table 1. Progression free and overall survival from the adjusted Cox proportional hazards models on 200 NSCLC patients (pts) stratified according to clinical and molecular scores individually and integrated into the DEMo score system.
| Score | # pts | Overall survival | Progression free survival | |||||
|---|---|---|---|---|---|---|---|---|
| HR* | 95% CI | P value | HR* | 95% CI | P value | |||
| Di Maio | ||||||||
| DiM_1 | 83 | 1 (ref) | – | – | 1 (ref) | – | – | |
| DiM_2 | 94 | 2.61 | 1.49–4.57 | 0.0008 | 1.70 | 1.04–2.77 | 0.0349 | |
| DiM_3 | 23 | 5.37 | 1.55–18.62 | 0.0080 | 2.29 | 0.77–6.87 | 0.1380 | |
| EPSILoN | ||||||||
| E_1 | 49 | 1 (ref) | – | – | 1 (ref) | – | – | |
| E_2 | 107 | 2.46 | 1.46–4.16 | 0.0007 | 2.67 | 1.38–3.72 | 0.0012 | |
| E_3 | 44 | 3.14 | 1.48–6.66 | 0.0029 | 2.68 | 1.30–5.56 | 0.0078 | |
| MSC risk levelǂ | ||||||||
| Low/intermediate | 118 | 1 (ref) | – | – | 1 (ref) | – | – | |
| High | 41 | 2.13 | 1.36–3.34 | 0.0009 | 1.72 | 1.12–2.64 | 0.0126 | |
| DEMo | ||||||||
| 3 | 29 | 1 (ref) | – | – | 1 (ref) | – | – | |
| 4 to 6 | 124 | 2.88 | 1.44–5.79 | 0.0029 | 3.43 | 1.85–6.36 | 0.0001 | |
| 7 to 9 | 47 | 13.13 | 3.85–44.81 | <0.0001 | 7.46 | 2.61–21.29 | 0.0002 | |
*, adjusted for age, sex, pack-year, line of therapy and ECOG performance status; ǂ, 41 patients with undetermined MSC results were excluded from the analysis. NSCLC, non-small cell lung cancer; MSC, microRNA signature classifier; HR, hazard ratio; CI, confidence interval; ref, reference.